[posting]38748939[/posting]Wir werden noch ein paar €´s mit Aktie einsacken ....
Neues Buy-Rating ..
With cash, the value of the pipeline increases considering the company can now move candidates forward. From Vista newsletter:
Raptor Pharmaceutical Corp. (RPTP)
Current Price: $1.95
Target Price: $5.55
Raptor announced that it completed its registered direct offering with institutional investors, raising an aggregate amount of approximately $7.5 million of gross proceeds (before placement agent fees and offering expenses) through the sale of 3,747,558 units. The units consist of one share of common stock and one warrant to purchase 0.5 of a share of common stock with a term of five years, and one warrant to purchase 0.5 of a share of common stock with a term of 18 months. Both warrants have an exercise price of $2.45 per share of common stock and are not exercisable for six months. This is highly encouraging news as the Company now has the necessary funds to move all of their clinical programs forward with a focus on DR Cysteamine, for the treatment of cystinosis. We believe the current sell off in the stock represents a tremendous buying opportunity considering the Company is approximately 12 months away from a potential FDA approval for DR cysteamine. We believe the company is worth at least $125M today based on our risk adjusted net present value calculation which is nearly 3 times the current share price. The value of the company will continue to increase with the continued advance of their clinical candidates.